Alkermes Plc (NASDAQ:ALKS) CEO Richard F. Pops sold 100,000 shares of Alkermes stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $20.18, for a total transaction of $2,018,000.00. Following the transaction, the chief executive officer now directly owns 816,433 shares in the company, valued at $16,475,617.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ ALKS traded up $0.14 during trading on Friday, reaching $20.26. 782,287 shares of the stock were exchanged, compared to its average volume of 842,901. The business’s 50-day moving average price is $21.52 and its 200 day moving average price is $26.84. Alkermes Plc has a twelve month low of $19.36 and a twelve month high of $45.16. The company has a quick ratio of 2.69, a current ratio of 2.98 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of -289.43 and a beta of 1.82.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Thursday, July 25th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.20. The business had revenue of $279.90 million for the quarter, compared to analysts’ expectations of $251.40 million. Alkermes had a negative net margin of 17.10% and a negative return on equity of 4.13%. The business’s revenue for the quarter was down 8.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.29 earnings per share. As a group, sell-side analysts expect that Alkermes Plc will post -0.39 earnings per share for the current fiscal year.

A number of research analysts have recently commented on the stock. Morgan Stanley raised shares of Alkermes from an “underweight” rating to an “equal” rating and reduced their target price for the stock from $30.00 to $20.00 in a research report on Thursday. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright assumed coverage on shares of Alkermes in a research report on Friday, May 31st. They set a “neutral” rating and a $28.00 target price on the stock. Piper Jaffray Companies reduced their target price on shares of Alkermes from $30.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Finally, TheStreet cut shares of Alkermes from a “c-” rating to a “d” rating in a research report on Friday, May 17th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.64.

A number of institutional investors and hedge funds have recently bought and sold shares of ALKS. Renaissance Technologies LLC raised its holdings in Alkermes by 139.7% in the second quarter. Renaissance Technologies LLC now owns 3,950,586 shares of the company’s stock valued at $89,046,000 after acquiring an additional 2,302,600 shares in the last quarter. BlackRock Inc. raised its holdings in Alkermes by 10.4% in the second quarter. BlackRock Inc. now owns 11,137,923 shares of the company’s stock valued at $251,050,000 after acquiring an additional 1,052,841 shares in the last quarter. AQR Capital Management LLC raised its holdings in Alkermes by 70.4% in the second quarter. AQR Capital Management LLC now owns 2,375,998 shares of the company’s stock valued at $53,080,000 after acquiring an additional 981,355 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Alkermes by 3.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,275,957 shares of the company’s stock valued at $457,020,000 after acquiring an additional 697,027 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in Alkermes by 29.1% in the first quarter. First Trust Advisors LP now owns 2,906,860 shares of the company’s stock valued at $106,071,000 after acquiring an additional 655,873 shares in the last quarter. 96.66% of the stock is currently owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Read More: Are we seeing the beginning of a new bubble?

Insider Buying and Selling by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.